MedTrace Logo

Glutathione (GSH) In The Treatment of Parkinson's Disease

NCT01177319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-08-09

No results posted yet for this study

Summary

This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.

Conditions

Interventions

DRUG

Glutathione

Sponsors & Collaborators

  • Wellness Health & Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • University of South Florida

    lead OTHER

Principal Investigators

  • Robert A Hauser, MD, MBA · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01177319 on ClinicalTrials.gov